Laminar Pharma Completes LAM561 Phase 2b/3 Trial Enrollment in Newly Diagnosed Glioblastoma, Topline OS Data Expected Q2 2027
核心洞察
Laminar Pharma (搜索) announced last patient, last visit in its 144-patient Phase 2b/3 trial of LAM561 plus standard of care in newly diagnosed glioblastoma (搜索), with topline overall survival results expected in Q2 2027.
The OS analysis will be triggered once 90 survival events are reached, a threshold already met, making the readout a function of data lock and analysis rather than further follow-up.
Interim unblinded data from March 2025 showed a potentially clinically relevant PFS improvement in MGMT (搜索)-methylated patients receiving LAM561, a subgroup where median OS historically reaches 23.4 months versus 12.6 months for unmethylated patients.
Laminar Pharma (搜索) has reached the last patient, last visit (LPLV) milestone in its international, multicenter, randomized, double-blind, placebo-controlled Phase 2b/3 trial evaluating LAM561 in combination with standard of care for patients with newly diagnosed glioblastoma (搜索). The Spanish biotech, headquartered in Palma de Mallorca, announced the completion on July 23, 2026, and confirmed that topline overall survival (OS) data are expected during the second quarter of 2027.
The 144-patient trial (NCT04250922) randomized participants 1:1 to receive either LAM561 plus standard of care — radiotherapy and temozolomide — or placebo plus standard of care. The primary efficacy endpoint is overall survival, with progression-free survival assessed using Response Assessment in Neuro-Oncology (RANO) criteria serving as a key secondary measure. The OS analysis is triggered once 90 survival events accumulate, a threshold the trial has already reached, meaning the Q2 2027 readout now depends on data lock and analysis rather than additional patient follow-up.
Interim Signal Points to MGMT (搜索)-Methylated Subgroup
The LPLV milestone follows interim unblinded data released in March 2025, after the Independent Data Monitoring Committee (IDMC) recommended in late 2024 that the study be unblinded and continue without modification. At that time, Laminar Pharma (搜索) reported a potential clinically relevant improvement in progression-free survival for MGMT (搜索)-methylated patients receiving LAM561 plus standard of care compared to the placebo control group.
The MGMT (搜索)-methylated subgroup has long been recognized as a biologically distinct cohort within glioblastoma (搜索). The landmark EORTC/NCIC analysis established that methylated patients achieve a median overall survival of 23.4 months versus 12.6 months for unmethylated patients, making this population the most plausible setting for incremental therapeutic gains. The interim PFS signal in this subgroup now represents the trial's most consequential variable heading into the OS readout.
"The 'last patient, last visit' is a milestone for Laminar Pharma (搜索) and brings us one step closer to our goal of delivering a much-needed therapy to patients battling one of the most aggressive forms of brain cancer," said Dr. Pablo Escribà, CEO of Laminar Pharma.
A Distinct Mechanism of Action
LAM561 (2-hydroxyoleic acid, also known as idroxioleic acid sodium) is an oral synthetic derivative of oleic acid that targets plasma membrane lipid composition in cancer cells rather than a conventional receptor or kinase pathway. The drug regulates membrane composition, reducing the activity of membrane-associated signaling proteins known to promote tumor growth. This membrane lipid therapy approach, termed Melitherapy by the company, represents a first-in-class mechanism distinct from existing glioblastoma (搜索) treatments.
Early-phase data in refractory glioma, published by Lopez et al. in the British Journal of Cancer (2023), established tolerability without the dose-limiting toxicities that have derailed several CNS programs. The safety profile observed throughout the Phase 2b/3 trial remained consistent with those prior studies, with the combination of LAM561 and standard of care proving well-tolerated among the 144 enrolled patients.
Compassionate Use and Post-Trial Access
Laminar Pharma (搜索) has implemented a compassionate use program for patients who demonstrated clinical benefit during the trial. Treating physicians may prescribe continued LAM561 treatment beyond study completion until marketing authorization is granted. This program, which the company frames as consistent with international ethical principles for post-trial access, extends the real-world evidence base and signals physician confidence in the therapy ahead of any regulatory submission.
The Stakes for 2027
Glioblastoma (搜索) remains the most common primary malignant brain tumor, accounting for nearly 50% of all gliomas and approximately 25% of all primary brain and CNS malignant tumors. Incidence in Europe exceeds 25,000 new cases annually, rising to over 100,000 cases per year worldwide. Despite temozolomide plus radiotherapy becoming the backbone of newly diagnosed GBM treatment in 2005, median overall survival has remained approximately 14.5 months. Approximately 15% of patients survive two years after diagnosis, and roughly 4% survive five or more years.
If the OS data confirm the PFS signal observed in the MGMT (搜索)-methylated subgroup, Laminar — headquartered in Mallorca, Spain, with a subsidiary in Massachusetts — would face a relatively straightforward path to a European regulatory submission. If the OS data fail to confirm the interim findings, the membrane lipid therapy platform loses its lead clinical proof point. Everything now hinges on the survival curves that will emerge from the data lock and analysis in the second quarter of 2027.